Navigation Links
Phase 2 Clinical Results of Ganite Plus Standard Therapy in,Patients with Relapsed/Refractory Lymphoma Presented at ASCO

products or product candidates; -- the Company's ability to enter into and successfully execute license and collaborative agreements, if any; -- the adequacy of the Company's capital resources and cash flow projections, and the Company's ability to obtain sufficient financing to maintain the Company's planned operations; -- the adequacy of the Company's patents and proprietary rights; -- the impact of litigation that has been brought against the Company and its officers and directors and any proposed settlement of such litigation; -- the Company's ability to regain compliance with the NASDAQ's listing qualifications, or its ability to successfully appeal the NASDAQ delisting; and -- the other risks described under Certain Risks and Uncertainties Related to the Company's Business, as contained in the Company's Annual Report on Form 10-K and Quarterly Report on Form 10-Q.

The Company does not undertake to update any forward-looking statements. There are a number of factors that could cause actual results and developments to differ materially. For a discussion of those risks and uncertainties, please see the Company's Annual Report on Form 10-K for 2006 and its most recent quarterly report on Form 10-Q.

     CONTACT:

     For Genta Incorporated

     Tara Spiess/Andrea Romstad

     TS Communications Group, LLC

     (908) 286-3980
info@genta.com

CONTACT: Tara Spiess or Andrea Romstad, both of TS Communications Group,LLC, +1-908-286-3980, , for Genta Incorporated info@genta.com

Web site: http://www.genta.com/http://www.idispharma.com/http://www.genta.com//

Ticker Symbol: (NASDAQ-NMS:GNTA)


'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
3. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
4. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
6. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
7. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
8. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
9. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
10. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
11. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
Post Your Comments:
(Date:10/8/2008)...atments for Spinal Cord, Other Nerve,Injuries -, ...protein that enables,nerve cells to communicate wi...developing nervous system. Research into how that ...rve cells may provide a basis for eventual,treatme...ous system,including spinal cord injury., "This ...
(Date:10/8/2008)...continued and Headcount to be Reduced, Summary: Ge...; Zanolimumab Program to be Discontinued and the ... Employees, COPENHAGEN, October 8 /P...unced today that it is discontinuing development o...sult of a portfolio review and,assessment of the o...
(Date:10/8/2008)...TAXUS(R) Element(TM) Platinum Chromium ... /- Boston Scientific,Corpo...ompleted enrollment in,the PERSEUS trial, designed...R) Element(TM) paclitaxel-eluting coronary stent. ...,500 patients at 100 U.S. and,international center...
(Date:10/8/2008)... -- Vical Incorporated (Nasdaq: VICL ),today is p...al data,demonstrating that the company,s Vaxfectin... protein-based infectious disease vaccines and,pep...m.D., Ph.D., Vical,s,Senior Vice President of Prod...esday, October 8, at the World Vaccine Congress (L...
Breaking Medicine Technology:Protein Shown to Play a Key Role in Normal Development of Nervous System 2Protein Shown to Play a Key Role in Normal Development of Nervous System 3Genmab A/S - Company Announcement: Genmab Reports Results of Portfolio 2Genmab A/S - Company Announcement: Genmab Reports Results of Portfolio 3Genmab A/S - Company Announcement: Genmab Reports Results of Portfolio 4Boston Scientific Completes Clinical Trial Enrollment for Third-Generation Drug-Eluting Stent 2Boston Scientific Completes Clinical Trial Enrollment for Third-Generation Drug-Eluting Stent 3Boston Scientific Completes Clinical Trial Enrollment for Third-Generation Drug-Eluting Stent 4Vical Expands Applications of Vaxfectin(R) Adjuvant for Infectious Disease and Cancer Vaccines; 80% to 100% of High-Dose Responders in H5N1 Clinical Trials Still Responding at 6 Months 2Vical Expands Applications of Vaxfectin(R) Adjuvant for Infectious Disease and Cancer Vaccines; 80% to 100% of High-Dose Responders in H5N1 Clinical Trials Still Responding at 6 Months 3Vical Expands Applications of Vaxfectin(R) Adjuvant for Infectious Disease and Cancer Vaccines; 80% to 100% of High-Dose Responders in H5N1 Clinical Trials Still Responding at 6 Months 4Vical Expands Applications of Vaxfectin(R) Adjuvant for Infectious Disease and Cancer Vaccines; 80% to 100% of High-Dose Responders in H5N1 Clinical Trials Still Responding at 6 Months 5Saving Lives of Florida Residents Who Develop Skin Cancer Each Year 3A The Key is Early Detection and Treatment 252 1Saving Lives of Florida Residents Who Develop Skin Cancer Each Year 3A The Key is Early Detection and Treatment 252 2CABI helps phase out dangerous pesticide in EU 356 1CABI helps phase out dangerous pesticide in EU 356 2Microbiotic technology developed for microinjection of zebrafish embryos 1069 1Family Dinners Shape Healthier Eating Habits 1065 1
...--May 15, 2007 - Synthetic Blood,International, In...,a statistical analysis of its Phase IIa study wit...ury. In line with preliminary,study results announ...d that the primary endpoint of increasing patients... met. Data also show a,decrease in patient glucose...
... 17, 2007 - Salix,Pharmaceuticals, Ltd. (NASDAQ:SL...r-initiated trials related to the Company,s produc...2007, which will be,held May 19-24, 2007. Digestiv...prestigious meeting in the world for the GI,profes...ysicians,researchers and academics from around th...
Other Medicine Technology:Positive Statistical Analysis from Synthetic Blood's Oxycyte,Traumatic Brain Injury Trial Indicates Achievement of Primary,Endpoint 2Positive Statistical Analysis from Synthetic Blood's Oxycyte,Traumatic Brain Injury Trial Indicates Achievement of Primary,Endpoint 3Salix Pharmaceuticals Previews Digestive Disease Week 2007 2Salix Pharmaceuticals Previews Digestive Disease Week 2007 3Salix Pharmaceuticals Previews Digestive Disease Week 2007 4Salix Pharmaceuticals Previews Digestive Disease Week 2007 5
(Date:10/10/2008)...10 /PRNewswire-FirstCall/ -- Hologic, Inc.,(Nasdaq...upplier of premium,diagnostics, medical imaging sy...he healthcare needs of women, today announced plan...erating results on Tuesday, November 11,2008 afte...anagement will,host a conference call on Tuesday, ...
(Date:10/10/2008)... Upon the completion of a highly successful CIO Fi...roudly announces their next business technology ga...ology executives in healthcare. CDM Media has conf...-12, 2009 at the Four Seasons Resort in Scottsdale...EB) October 11, 2008 -- Upon the completion of a h...
(Date:10/10/2008)... 10 /PRNewswire/ -- NuView Life Sciences Inc.,(NuV... Sciences Inc.,(Trace), including operations of th...lities in Denton, Texas. The Trace facility produc...nd Thallium-201 used in,molecular imaging and nucl... stated that "We are confident that by improving o...
(Date:10/10/2008)...Calif., Oct. 10 /PRNewswire/ -- A senior citizen,s...ountains in a small,plane. The high-flying adventu.... The thrill came from a last-wish program through...nior Living, where Heden was a patient.,Called Go ...it has helped,many realize a special activity at t...
Breaking Medicine News(10 mins):Health News:Hologic, Inc. To Release Fourth Quarter and Fiscal 2008 Operating Results on Tuesday, November 11, 2008 2Health News:CIO Healthcare Summit Announces Dates and VIP Delegates 2Health News:Deck of Cards is More Than a Game: Integral in Silverado Hospice Care 2
...ork-Presbyterian Hospital/Weill Cornell Medical Ce...nts the ability of an antibody to directly target ...ing healthy tissues unharmed. The Phase I clinica..., targeted to the prostate specific membrane antig...
...y 40% of the doctors in one Russian city have late...ho work in TB clinics. The research has been publi...oblem worldwide. Russia is one country where it is... third of the world's population are infected with...
... standard breast cancer therapy drug tamoxifen, to...s by almost one-fifths. Publishing their finding... Dr. Francesco Boccardo of the National Cancer Res... changing treatments tracks to exemestane after 2 ...
...r from persistent iron overload has been cleared. ...um. Patients suffering from a rare genetic condit...se need regular blood transfusions. Generally thes... at nights by needle and pump which lasts for arou...
Other Medicine News:Health News:First Treatment to Directly Target Tumor Blood Supply 2Health News:First Treatment to Directly Target Tumor Blood Supply 3Health News:New Drug Therapy for Breast Cancer Offers Hope 2
...dy (IgG) Test is a semiquantitative enzyme immunoa...cant IgG antibodies to M. pneumoniae between acute...should not be used for specimens found reactive wi... Test and is not intended for qualitative (one spe...
...unoassay (EIA) that detects IgG antibodies to Epst...arr early nuclear antigen (EBV-EBNA), cytomegalovi...n with Mono-M Test it is an aid in the serodiagnos...ve serodiagnosis of CMV or Toxoplasma mononucleosi...
The ImmunoDOT TORCH Test is an enzyme immunoassay (EIA) procedure intended for determining the presence of antibodies to Toxoplasma gondii, rubella virus, cytomegalovirus and herpes simplex virus in
...e enzyme immunoassays (EIA) for the presumptive de... IgM, respectively) in serum. Equivocal or positiv...with a standardized western blot procedure. These ...ical diagnosis of B. burgdorferi infection (Lyme d...
Medicine Products: